疫情后的价值回归是必_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

大道在东方
2023-08-18

疫情后的价值回归是必然的，另外美国经济衰落的预期，导致各大企业都在不断裁员，缩减开支，docs能在这时候发表收入减少，显示了它快速的反应以及消息的灵通

Time to Cut and Run on This 1 Formerly Promising Digital Health Stock?

It's time to shorten the leash on Doximity after a surprise about-face on financial guidance.

Time to Cut and Run on This 1 Formerly Promising Digital Health Stock?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":210075953741912,"tweetId":"210075953741912","gmtCreate":1692309521160,"gmtModify":1692309581869,"author":{"id":3567572894347438,"idStr":"3567572894347438","authorId":3567572894347438,"authorIdStr":"3567572894347438","name":"大道在东方","avatar":"https://static.tigerbbs.com/3c5fdc0db8c3646b57d40af40a2a0048","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>疫情后的价值回归是必然的，另外美国经济衰落的预期，导致各大企业都在不断裁员，缩减开支，docs能在这时候发表收入减少，显示了它快速的反应以及消息的灵通</p></body></html>","htmlText":"<html><head></head><body><p>疫情后的价值回归是必然的，另外美国经济衰落的预期，导致各大企业都在不断裁员，缩减开支，docs能在这时候发表收入减少，显示了它快速的反应以及消息的灵通</p></body></html>","text":"疫情后的价值回归是必然的，另外美国经济衰落的预期，导致各大企业都在不断裁员，缩减开支，docs能在这时候发表收入减少，显示了它快速的反应以及消息的灵通","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/210075953741912","repostId":2358010516,"repostType":2,"repost":{"id":"2358010516","kind":"highlight","pubTimestamp":1691806020,"share":"https://www.laohu8.com/m/news/2358010516?lang=&edition=full","pubTime":"2023-08-12 10:07","market":"us","language":"en","title":"Time to Cut and Run on This 1 Formerly Promising Digital Health Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2358010516","media":"Motley Fool","summary":"It's time to shorten the leash on Doximity after a surprise about-face on financial guidance.","content":"<html><body><div><p>There's a big difference between being in the right place at the right time and executing well on a business opportunity. After a few years of stellar growth during the pandemic, it suddenly looks like <strong>Doximity </strong><span>(DOCS<span> -4.38%</span>)</span> -- like so many other pandemic-era growth stories -- falls in the former category.</p><p>I don't say this simply because its shares plunged more than 20% after recent earnings, putting it in camp with quite a few other small stocks that haven't held up so well during this summer's earnings season. Rather, it looks like management was really out of touch when touting their ambitious growth plans.</p><p>Here's what investors need to know.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"344751\" :show_benchmark_compare=\"false\" amount_change=\"-1.09\" average_volume=\"2,252,026\" company_name=\"Doximity\" current_price=\"23.82\" daily_high=\"24.68\" daily_low=\"23.59\" default_period=\"OneMonth\" dividend_yield=\"N/A\" exchange=\"NYSE\" fifty_two_week_high=\"40.12\" fifty_two_week_low=\"22.91\" gross_margin=\"87.74\" logo=\"https://g.foolcdn.com/art/companylogos/mark/DOCS.png\" market_cap=\"$5B\" pe_ratio=\"45.03\" percent_change=\"-4.38\" symbol=\"DOCS\" volume=\"6,236,265\"></app></div><h2>Hyperfocus on its niche turns against Doximity</h2><p>Let's cut right to the chase here and consider the main issue: financial guidance. Just two months after its investor day and calling for an average annual revenue growth rate of 20% through 2028, management severely revised revenue guidance for its fiscal 2024 (the 12 months that will end in March 2024) down to just -- wait for it -- 10% at the midpoint.</p><p>The new outlook is for revenue to be in the range of $452 million to $468 million, down from the prior outlook of $500 million to $506 million. Ouch! I'll reiterate, this is just two months after touting its ability to upsell software services to the myriad of doctors, physicians, and healthcare companies that use its Doximity app -- often referred to as \"the LinkedIn for medical professionals.\"</p><div><div></div></div><div><img loading=\"lazy\" src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743644%2Fdocs-june-2023.png&amp;op=resize&amp;w=700\" srcset=\"https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/743644/docs-june-2023.png&amp;w=300&amp;op=resize 300w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/743644/docs-june-2023.png&amp;w=1000&amp;op=resize 1000w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/743644/docs-june-2023.png&amp;w=2000&amp;op=resize 2000w\"/><p>A chart from Doximity's June 2023 Investor Day showing its expectation for 20% average annual sales growth over the next four years. Image source: Doximity. CAGR = compound annual growth rate.</p></div><p>You see, much of this business' sales come from advertising campaigns on its app (including all of the top 20 pharmaceutical and hospital giants). Doximity says its customers get exceptional return on investment from marketing on the app, and the company has historically turned that into upsell opportunities for more marketing -- and, more recently, the upsell of app extensions like video conferencing and e-signature.</p><p>We already knew that marketing campaign budgets were under pressure this year, as that's often the first budgetary item cut when the economy slows. But that's not the issue here. Co-founder and CEO Jeff Tangey explained on the earnings call:</p><blockquote><p>It's the friction of our full-service, white-glove sales model. Simply put, during summer upsell season, clients no longer have the time to schedule all of the meetings, legal reviews, reports, and [quarterly business reviews]. Post COVID, they work from home most of the week, and they'd rather log in to a self-service platform 24/7 to monitor their program results and set budgets.</p></blockquote><p>In other words, the one-on-one high-touch service that has gotten Doximity to this point isn't working anymore. As Tangey further explained, customers \"want to expand and adjust their programs onto Doximity with the click of a button, just like they would on LinkedIn, Facebook, <strong>Amazon</strong>, or Google.\" Automation is the future, and the company is scrambling to get a self-service portal up and running for all its customers.</p><div><div></div></div><h2>Time to sell?</h2><p>The recent revision surprises me in more ways than one. Sure, it's the quick about-face on full-year guidance. But as the healthcare system pivots to digital tools, it seems like the need for an automated self-service system would have been more obvious.</p><p>At any rate, the revision downwards is quite large. Interestingly, the long-term guide through 2028 was reiterated, but I believe that needs to be tossed into the \"hopes and dreams\" file versus the \"realistic expectations\" one at this point. D</p><p>On the positive side, Doximity is still growing modestly, it's highly profitable, has $873 million in cash and short-term investments and no debt, and will be completing the $233 million in share buybacks currently authorized.</p><div><div></div></div><p>However, the shares currently trade for about 24 times the expected full-year adjusted EBITDA (earnings before interest, tax, depreciation, and amortization). Given the lowered financials, it doesn't look particularly cheap for a small and low-growth business.</p><p>All of that aside, though, it appears Doximity was in the right place at the right time for the pandemic-era push into digital workflows but it is not executing as was hoped on its opportunity. It's time to shorten the leash on this one. If things don't improve soon, I'll be selling.</p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Cut and Run on This 1 Formerly Promising Digital Health Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Cut and Run on This 1 Formerly Promising Digital Health Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-12 10:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/08/12/time-to-cut-and-run-on-this-1-formerly-promising/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a big difference between being in the right place at the right time and executing well on a business opportunity. After a few years of stellar growth during the pandemic, it suddenly looks ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/08/12/time-to-cut-and-run-on-this-1-formerly-promising/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743644%2Fdoctor-healthcare-technology-apps.jpg&op=resize&w=165&h=104","relate_stocks":{"BK4539":"次新股","DOCS":"Doximity, Inc.","BK4551":"寇图资本持仓","BK4167":"医疗保健技术","BK4585":"ETF&股票定投概念"},"source_url":"https://www.fool.com/investing/2023/08/12/time-to-cut-and-run-on-this-1-formerly-promising/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2358010516","content_text":"There's a big difference between being in the right place at the right time and executing well on a business opportunity. After a few years of stellar growth during the pandemic, it suddenly looks like Doximity (DOCS -4.38%) -- like so many other pandemic-era growth stories -- falls in the former category.I don't say this simply because its shares plunged more than 20% after recent earnings, putting it in camp with quite a few other small stocks that haven't held up so well during this summer's earnings season. Rather, it looks like management was really out of touch when touting their ambitious growth plans.Here's what investors need to know.Hyperfocus on its niche turns against DoximityLet's cut right to the chase here and consider the main issue: financial guidance. Just two months after its investor day and calling for an average annual revenue growth rate of 20% through 2028, management severely revised revenue guidance for its fiscal 2024 (the 12 months that will end in March 2024) down to just -- wait for it -- 10% at the midpoint.The new outlook is for revenue to be in the range of $452 million to $468 million, down from the prior outlook of $500 million to $506 million. Ouch! I'll reiterate, this is just two months after touting its ability to upsell software services to the myriad of doctors, physicians, and healthcare companies that use its Doximity app -- often referred to as \"the LinkedIn for medical professionals.\"A chart from Doximity's June 2023 Investor Day showing its expectation for 20% average annual sales growth over the next four years. Image source: Doximity. CAGR = compound annual growth rate.You see, much of this business' sales come from advertising campaigns on its app (including all of the top 20 pharmaceutical and hospital giants). Doximity says its customers get exceptional return on investment from marketing on the app, and the company has historically turned that into upsell opportunities for more marketing -- and, more recently, the upsell of app extensions like video conferencing and e-signature.We already knew that marketing campaign budgets were under pressure this year, as that's often the first budgetary item cut when the economy slows. But that's not the issue here. Co-founder and CEO Jeff Tangey explained on the earnings call:It's the friction of our full-service, white-glove sales model. Simply put, during summer upsell season, clients no longer have the time to schedule all of the meetings, legal reviews, reports, and [quarterly business reviews]. Post COVID, they work from home most of the week, and they'd rather log in to a self-service platform 24/7 to monitor their program results and set budgets.In other words, the one-on-one high-touch service that has gotten Doximity to this point isn't working anymore. As Tangey further explained, customers \"want to expand and adjust their programs onto Doximity with the click of a button, just like they would on LinkedIn, Facebook, Amazon, or Google.\" Automation is the future, and the company is scrambling to get a self-service portal up and running for all its customers.Time to sell?The recent revision surprises me in more ways than one. Sure, it's the quick about-face on full-year guidance. But as the healthcare system pivots to digital tools, it seems like the need for an automated self-service system would have been more obvious.At any rate, the revision downwards is quite large. Interestingly, the long-term guide through 2028 was reiterated, but I believe that needs to be tossed into the \"hopes and dreams\" file versus the \"realistic expectations\" one at this point. DOn the positive side, Doximity is still growing modestly, it's highly profitable, has $873 million in cash and short-term investments and no debt, and will be completing the $233 million in share buybacks currently authorized.However, the shares currently trade for about 24 times the expected full-year adjusted EBITDA (earnings before interest, tax, depreciation, and amortization). Given the lowered financials, it doesn't look particularly cheap for a small and low-growth business.All of that aside, though, it appears Doximity was in the right place at the right time for the pandemic-era push into digital workflows but it is not executing as was hoped on its opportunity. It's time to shorten the leash on this one. If things don't improve soon, I'll be selling.","news_type":1},"isVote":1,"tweetType":1,"viewCount":561,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":141,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}